fibrocystic breast change

fibrocystic breast change

A nonspecific diagnosis for a benign condition characterized by palpable lumps in the breasts, usually associated with pain and tenderness. At least 50% of women of reproductive age have palpably irregular breasts caused by this condition. This benign condition was formerly known as fibrocystic disease of the breast See: breast self-examination

Women with marked lumpiness in one or both breasts have a two to five times greater risk of developing breast cancer. If hyperplasia is present in the lesion, or if there is a family history of breast cancer, the risk of developing breast cancer is greatly increased. Women should practice breast self-examination once a month, about a week after the menstrual period, have a clinician breast exam every 6 months, and, if indicated, a mammography once a year or other screening tests as recommended by their health care providers. Any palpable, distinct, or dominant mass requires immediate evaluation


Some women obtain relief by reducing fat intake in the diet to less than 25%, limiting salt intake premenstrually, eliminating caffeine, foods containing methylxanthines, tobacco products, and alcohol, or by taking complementary remedies such as vitamin E supplements. Occasionally providers may prescribe danazol, an androgenic (male) hormone. Patients with benign symptomatic nodularity or mastalgia often respond well to low-dose oral contraceptives.

Patient care

Emotional support is provided for women who have a heightened awareness or fear of developing breast cancer. Instructing the patient includes discussion and demonstration of breast self-examination, with emphasis placed on the importance of monthly self-exams, periodic mammography, and annual examinations by a health care professional. The accuracy of the patient's self-exam is evaluated by asking her to locate any currently palpable lumps and to describe the present contour and texture (feel) of her breasts (mapping).

If pain and tenderness are bothersome, suggestions include taking aspirin or other nonsteroidal anti-inflammatory over-the-counter drugs and wearing a well-fitting brassiere day and night.

Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
Fibrocystic breast change (FBC), aka fibrocystic breast disease (FBD), is a benign disorder of the breasts that can result in lumpiness, nodules, and/or pain.
A randomized controlled multicenter trial of an investigational liquid nutritional formula in women with cyclic breast pain associated with fibrocystic breast changes. J Women's Health.
The concept of clinging carcinoma in situ was introduced by Azzopardi1 in 1979 in his remarkable book Problems in Breast Pathology to describe a distinct atypical intraepithelial lesion of the breast that can be mistaken for either normal breast tissue or ordinary fibrocystic breast change. Judging from his book, the idea of clinging carcinoma in situ as a distinct neoplastic lesion began after overlooking a case with severe cytologic epithelial atypia.
A review of mastalgia in patients with fibrocystic breast changes and the non-surgical treatment options.
A related myth is that women who have fibrocystic breast changes (when breast tissue becomes lumpy) are at higher risk for breast cancer.
"Fibrocystic breast changes are a different issue," says Dr.
Although once considered a disease, most experts now prefer to call them "fibrocystic breast changes." Fibrocystic breast changes are caused by fibroadenoma (which occurs in a much younger age) and fibroadenosis which usually occurs after 35 years.
The cause of fibrocystic breast changes isn't completely understood.
For many years it was thought that fibrocystic breast changes, very common findings in women, predispose an individual to developing breast cancer.
In lieu of any credible evidence that high-dose iodine is beneficial (other than for patients with fibrocystic breast changes or a few other clinical conditions), routine use of high-dose iodine should cease.
Two hundred thirty-three women with fibrocystic breast changes received Lugol's iodine (consisting of 95% iodide and 5% iodine) orally for two years.
The results of the present study indicate that iodine supplementation is beneficial for a majority of women with fibrocystic breast changes. The dosage of iodine used in this study was more than 30 times the Recommended Dietary Allowance.